Create your account for 2 FREE subscriber-only articles each month. Get Free Access Now.
Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with NEJM Group information and services.
Stay connected to what’s important in medical research and clinical practice
Subscribe to the most trusted
and influential source of
medical knowledge
Already a subscriber? Renew or Sign in
Subscribe
or Renew
Selected specialties
View all specialties
Selected Topics
View all topics
Selected Multimedia
View all multimedia
Current Issue
Recent Issues
Browse full issue index
Recently Published Articles
Browse recently published
View all learning/CME
Other NEJM Group Learning
Subscribe
or Renew
This article is available to subscribers. Subscribe now. Already have an account? Sign in
CorrespondenceFree Preview
To the Editor: Arslanian et al. (Aug. 4 issue)1 report that a once-weekly subcutaneous injection of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, at a dose of 0.75 mg or 1.5 mg was superior to placebo in improving blood glucose control in overweight pediatric patients (10 to <18 years of age) with type 2 diabetes. Notably, 40% of the children were under 14 years of age. The average height of the children was 162.4±9.2 cm, which suggests that they had not yet reached their adult height. A previous study2 of GLP-1 receptor agonists showed their potential role in an increase . . .
Select an option below:
Are you a member of an institution such as a university or hospital?
Learn more about Institutional Access
October 20, 2022
N Engl J Med 2022; 387:1529-1531
DOI: 10.1056/NEJMc2211623
Print Subscriber? Activate your online access.
Related Articles
Back to top
Diabeets
20/10/2022
